William Blair Analysts Confident on Tenaya Therapeutics (TNYA) Product Pipeline [Yahoo! Finance]
Tenaya Therapeutics, Inc. (TNYA)
Company Research
Source: Yahoo! Finance
Hsieh of William Blair maintained a Buy rating on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) on March 12, expressing a positive outlook for the stock. His view is supported by the company's advancing pipeline and improving regulatory clarity. Expected alignment with regulators on the pivotal trial designs for TN-201 and TN-401 could serve as a major de-risking event, offering clearer approval pathways and better visibility on potential value drivers and timelines. Momentum into 2026 is backed by resumed enrollment in the MyPEAK-1 study for TN-201 and positive DSMB safety feedback on TN-401, allowing dose expansion. Early data from TN-301 is also important, as it expands the platform beyond gene therapy and could add a third growth pillar, supported by sufficient capital to execute current plans. Tenaya Therapeutics, Inc. (NASDAQ:TNYA) reported its fourth-quarter results on March 11, posting a GAAP EPS of -$0.12, which came in line with expectations. As of December 31, 2025, the compa
Show less
Read more
Impact Snapshot
Event Time:
TNYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNYA alerts
High impacting Tenaya Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNYA
News
- Tenaya Therapeutics, Inc. (TNYA) Reports Q4 EPS of (12c), In Line with Consensus [Yahoo! Finance]Yahoo! Finance
- Tenaya Therapeutics (TNYA) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TNYA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hoMarketBeat
- Tenaya Therapeutics (TNYA) had its "outperform" rating reaffirmed by Leerink Partners.MarketBeat
- Tenaya Therapeutics (TNYA) had its "outperform" rating reaffirmed by William Blair.MarketBeat
- Tenaya Therapeutics (TNYA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $8.00 price target on the stock.MarketBeat
TNYA
Earnings
- 3/11/26 - Beat
TNYA
Sec Filings
- 3/11/26 - Form 10-K
- 3/11/26 - Form 8-K
- 3/5/26 - Form 8-K
- TNYA's page on the SEC website